Errico emphasized the clinical foundation supporting electroCore’s non-invasive vagus nerve stimulation (nVNS) platform. He said the company’s flagship gammaCore device is supported by more than 20 peer-reviewed publications and multiple randomized controlled trials, including ACT-one, ACT-two, PRESTO, and PREMIUM, which he said demonstrated statistically significant reductions in migraine and cluster headache frequency, intensity, and duration. Errico noted gammaCore is FDA-cleared for both acute and preve ...